Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Multiple Myeloma
Clinical trial register · United States · industry-sponsored

Multiple Myeloma Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 63 Georgia 57 Florida 56 Colorado 41 Arizona 38
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC23 AbbVie13 GlaxoSmithKline12 Pfizer8 Celgene5
State
California63 Georgia57 Florida56 Colorado41 Arizona38
All 42 states
Target enrolment
to

Multiple Myeloma trials in the USA

110 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Fortvita Biologics (USA)Inc.
Phase 1/2
360
Arizona, California, Georgia, New York, Texas
2026-09-30
Not yet open
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
NCT07679919Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Multiple Myeloma
DrugLMY-922
Luminary Therapeutics
Phase 1
27
Ohio
2026-09
Recruiting
Janssen Research & Development, LLC
Phase 2
230
Arizona, California, Colorado, Missouri
2026-06-30
Recruiting
Hoffmann-La Roche
Phase 3
380
California, Connecticut, District of Columbia, Georgia, North Carolina, Ohio, West Virginia
2026-06-23
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-31
Recruiting
GlaxoSmithKline
Phase 2
200
California, Connecticut, Florida, Georgia, Louisiana, Maryland, Missouri, New Mexico
2026-04-15
Recruiting
AbbVie
Phase 1
127
California, Colorado, Florida, Georgia, Illinois, Michigan
2026-02-27
Recruiting
C4 Therapeutics, Inc.
Phase 2
100
Alabama, Arizona, California, Florida, Georgia, Indiana, Iowa, Michigan
2026-02-18
Active, closed
Janssen Research & Development, LLC
Phase 2
168
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2026-02-08
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-02-04
Recruiting
Takeda
Phase 3
183
Alabama, California, Kansas, Maryland, Michigan, Missouri, New York
2026-01-14
Recruiting
AbbVie
Phase 2/3
680
Arizona, California, Colorado, Georgia, Indiana, Minnesota, New York, North Carolina
2026-01-08
Active, closed
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
NCT06323447Diffuse Large B Cell Lymphoma, Multiple Myeloma
Leuko Labs, Inc.
Observational
210
Hawaii, Kentucky, Massachusetts, New Jersey, Texas
2025-12-15
Recruiting
Celgene
Phase 1/2
62
Alabama, Connecticut, New Jersey, Texas
2025-10-07
Recruiting
Janssen Research & Development, LLC
Phase 2
60
California, Florida, Iowa, New York, North Carolina, Ohio
2025-10-03
Recruiting
AbbVie
Phase 1
135
California, Colorado, Missouri, New Jersey, New York, North Carolina, Washington
2025-08-07
Recruiting
AstraZeneca
Phase 1
40
Arizona, California, Colorado, Florida, Georgia, Iowa, Minnesota, Missouri
2025-07-31
Recruiting
AbbVie
Phase 1/2
325
California, Connecticut, Massachusetts, Michigan, New York, North Carolina, Oregon, Texas
2025-07-23
Recruiting
AbbVie
Phase 1/2
602
California, Colorado, Florida, Georgia, New York, North Carolina, Ohio, Texas
2025-06-30
Recruiting
GlaxoSmithKline
Phase 3
520
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Maine
2024-12-16
Recruiting
Janssen Research & Development, LLC
Phase 1
276
Colorado, Georgia
2024-12-04
Active, closed
Janssen Research & Development, LLC
Phase 2
11
Iowa, Kentucky, Michigan, New York, Pennsylvania
2024-09-16
Active, closed
Cullinan Therapeutics Inc.
Phase 1
30
Arizona, Florida, Minnesota, New York, North Carolina, Texas
2024-09-03
Recruiting
Janssen Research & Development, LLC
Phase 2
210
California, Colorado, Connecticut, New York, North Carolina, Ohio, Virginia, Washington
2024-08-26
Active, closed
Kite, A Gilead Company
Phase 3
452
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2024-08-23
Active, closed
Janssen Research & Development, LLC
Phase 2
43
California, Iowa, New York, North Carolina
2024-08-20
Active, closed
AbbVie
Phase 1
60
Arizona, Florida, Michigan, Minnesota, North Carolina, Wisconsin
2024-06-17
Active, closed
Janssen Research & Development, LLC
Phase 1
108
Arizona, Colorado, Florida, Georgia, Indiana, Ohio, Texas
2024-06-07
Active, closed
AbbVie
Phase 3
421
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana
2024-05-19
Recruiting
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
NCT06149910Multiple Myeloma, Multiple Myeloma Without Mention of Remission
All4Cure
Observational
450
Washington
2024-04-18
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
230
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-03-21
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
187
Alabama, Arizona, California, Florida, Georgia, Massachusetts, Minnesota, Nebraska
2024-02-22
Active, closed
Pfizer
Phase 1
100
Florida, Georgia, Indiana, Maryland, Massachusetts, Nebraska, New Hampshire, New Jersey
2024-02-20
Recruiting
Pfizer
Phase 3
492
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas
2024-02-08
Active, closed
Janssen Research & Development, LLC
Phase 3
838
California, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Iowa
2024-01-22
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
149
California, Colorado, Kentucky, Michigan, New Jersey, New York, North Carolina, Texas
2023-12-19
Recruiting
AstraZeneca
Phase 1/2
226
California, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Virginia
2023-12-05
Recruiting
Indapta Therapeutics, INC.
Phase 1/2
128
California, Florida, Georgia, Minnesota, New York, North Carolina, Ohio, Oregon
2023-10-25
Active, closed
Celgene
Phase 3
79
California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan, Minnesota
2023-10-16
Recruiting
Bristol-Myers Squibb
Observational
50
Oregon, Texas, Utah, Wisconsin
2023-10-06
Recruiting
Pfizer
Phase 4
80
California, Colorado, Florida, Michigan, Texas
2023-10-03
Recruiting
Starton Therapeutics, Inc
Phase 1/2
24
North Carolina, Ohio
2023-10-02
Recruiting
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
NCT05956457Multiple Myeloma, Relapsed Hematologic Malignancy
Pack Health
Not applicable
100
Washington
2023-09-15
Recruiting
Carevive Systems, Inc.
Observational
25
Connecticut, Illinois, North Carolina, Ohio
2023-07-19
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Colorado, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2023-06-22
Recruiting
GlaxoSmithKline
Phase 1/2
123
Arizona, California, Florida, Massachusetts, Michigan, North Carolina, Ohio, Tennessee
2023-06-14
Recruiting
AbbVie
Phase 1
210
Arizona, Arkansas, Colorado, Delaware, Illinois, Indiana, Louisiana, Maryland
2023-03-21
Active, closed
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
NCT05673083Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory, Multiple Myeloma With Failed Remission
All4Cure
Observational
200
Arkansas, Florida, Iowa, New York, Oklahoma, Texas, Washington
2023-03-01
Recruiting
K36 Therapeutics, Inc.
Phase 1
165
California, Florida, Georgia, Massachusetts, Minnesota, New Jersey, New York, North Carolina
2023-02-22
Active, closed
Janssen Research & Development, LLC
Phase 3
213
Florida, Georgia, Michigan, Missouri, New York, Texas
2022-12-15
Active, closed
Pfizer
Phase 1
59
Arkansas, California, Florida, Georgia, Iowa, Maryland, Massachusetts, New Jersey
2022-12-14
Recruiting
Oncotherapeutics
Early Phase 1
30
California
2022-12-08
Recruiting
Pfizer
Phase 3
1,060
Florida, Nebraska, Nevada, New Jersey, New York, Texas, Utah
2022-11-10
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa
2022-10-25
Recruiting
Bristol-Myers Squibb
Phase 1/2
260
Alabama, Maryland, Massachusetts, New Jersey, New York
2022-10-18
Active, closed
Hoffmann-La Roche
Phase 1/2
90
Colorado, Florida, Maryland, Massachusetts, Minnesota, New York, Tennessee, Utah
2022-10-17
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Arizona, Arkansas, Connecticut, District of Columbia, Florida, Illinois, Kansas, Louisiana
2022-10-13
Active, closed
Carevive Systems, Inc.
Not applicable
100
Ohio
2022-10-06
Recruiting
Regeneron Pharmaceuticals
Phase 1
317
California, Georgia, Indiana, Massachusetts, Michigan, Minnesota, New York, North Carolina
2022-08-17
Active, closed
GlaxoSmithKline
Phase 1/2
20
Massachusetts
2022-07-19
Active, closed
Kite, A Gilead Company
Phase 2
136
Arizona, Arkansas, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2022-07-15
Active, closed
Celgene
Phase 3
939
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2022-06-23
Recruiting
Pack Health
Not applicable
50
Texas, Washington
2022-06-17
Recruiting
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
NCT04771572Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia
Newave Pharmaceutical Inc
Phase 1
100
Illinois, Massachusetts, North Carolina, Ohio, Texas, Utah
2022-05-08
Active, closed
Poseida Therapeutics, Inc.
Phase 1
275
Arizona, California, Georgia, Illinois, Iowa, Kansas, Maryland, Michigan
2022-05-05
Active, closed
Pfizer
Phase 3
854
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kansas, Michigan
2022-03-25
Recruiting
Janssen Research & Development, LLC
Phase 4
295
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Massachusetts
2022-03-09
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
California, Colorado, District of Columbia, Florida, Illinois, Maryland, Massachusetts, New Jersey
2022-02-28
Recruiting
Heidelberg Pharma AG
Phase 1/2
78
Georgia, Kentucky, Nebraska, New York, Texas
2022-02-07
Active, closed
Janssen Research & Development, LLC
Phase 3
587
Alabama, California, Connecticut, Georgia, Massachusetts, Michigan, Ohio, Pennsylvania
2021-10-14
Recruiting
Pfizer
Phase 3
893
California, Colorado, Florida, Louisiana, New Jersey, New York
2021-10-04
Active, closed
Janssen Research & Development, LLC
Phase 1
166
Alabama, California, Colorado, Georgia, Indiana, New Jersey, New York, North Carolina
2021-09-22
Active, closed
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
NCT04782687Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell
DrugsDarzalex·Selinexor·Daratumumab·Lenalidomide
US Oncology Research
Phase 2
73
Arizona, Colorado, Maryland, New York, Oregon, Texas, Virginia
2021-09-10
Active, closed
Janssen Research & Development, LLC
Phase 3
743
California, Connecticut, Florida, Iowa, Kentucky, Maryland, Massachusetts, Michigan
2021-08-19
Active, closed
GlaxoSmithKline
Phase 1/2
30
Georgia, Massachusetts, Michigan, Wisconsin
2021-07-29
Recruiting
Genentech, Inc.
Phase 1
186
California, Colorado, Georgia, Michigan, Missouri
2021-07-26
Active, closed
C4 Therapeutics, Inc.
Phase 1
224
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Minnesota, Missouri
2021-04-27
Active, closed
Janssen Research & Development, LLC
Phase 1
140
Alabama, California, Colorado, Georgia, Indiana, Missouri, New Jersey, New York
2021-03-12
Active, closed
Pfizer
Phase 2
187
California, Florida, Georgia, Illinois, Kentucky, Louisiana, New Jersey, New York
2021-02-02
Active, closed
Janssen Research & Development, LLC
Phase 1/2
228
Alabama, Arkansas, Colorado, Georgia, Minnesota, Missouri, New York, North Carolina
2020-12-15
Active, closed
GlaxoSmithKline
Phase 3
302
Arizona, Florida, Massachusetts, Missouri, Tennessee
2020-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
419
Alabama, Arizona, California, Colorado, Connecticut, Florida, Iowa, Kansas
2020-06-12
Active, closed
GlaxoSmithKline
Phase 1/2
106
Georgia, Massachusetts, Michigan, Wisconsin
2020-06-08
Active, closed
GlaxoSmithKline
Phase 3
494
Arizona, Colorado, Kansas, Ohio, Texas
2020-05-07
Active, closed
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
NCT04184050Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1
100
Arizona, California, Kansas, New York, Oregon, Washington
2020-04-13
Active, closed
GlaxoSmithKline
Phase 3
325
Arizona, Colorado, Michigan, Nebraska, New York, Ohio, Oregon, Texas
2020-04-02
Active, closed
Janssen Research & Development, LLC
Phase 1
290
California, New York, North Carolina, Pennsylvania, Tennessee, Wisconsin
2020-02-21
Active, closed
GlaxoSmithKline
Phase 1
118
Kansas, North Carolina, Wisconsin
2019-12-18
Active, closed
GlaxoSmithKline
Phase 1/2
25
Georgia, Wisconsin
2019-11-26
Active, closed
Janssen Research & Development, LLC
Phase 2
208
California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Kansas
2019-11-07
Active, closed
GlaxoSmithKline
Phase 1/2
208
Georgia, Indiana, Massachusetts, Michigan, Wisconsin
2019-10-07
Active, closed
Celgene
Phase 1/2
424
Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota, New Jersey
2019-09-30
Active, closed
CARsgen Therapeutics Co., Ltd.
Phase 1/2
105
Arizona, California, Colorado, Florida, Massachusetts, Minnesota, Tennessee, Texas
2019-09-25
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
DrugsVenclexta·Venetoclax
AbbVie
Phase 3
165
Arizona, California, Illinois, Massachusetts, Michigan, New Hampshire, Washington
2019-09-06
Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma
DrugsIxazomib·Elranatamab·Teclistamab·Pomalidomide
CellCentric Ltd.
Phase 1/2
250
Georgia, Indiana, Maryland, Nebraska, Pennsylvania
2019-08-09
Active, closed
AbbVie
Phase 1/2
220
California, Louisiana, Minnesota, Missouri, New York, North Carolina, Wisconsin
2019-06-24
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
387
Florida, Georgia, Indiana, Kentucky, Michigan, New Jersey, New York, Ohio
2019-01-23
Active, closed
Poseida Therapeutics, Inc.
Phase 1
100
California, Colorado, Illinois, Kansas, Maryland, Michigan, Pennsylvania, Tennessee
2018-10-29
Active, closed
AbbVie
Phase 3
265
Arizona, California, Colorado, Florida, Kentucky, Maryland, Massachusetts, Michigan
2018-10-22
By invitation
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
NCT03628612Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric
Autolus Limited
Phase 2
500
Florida, Missouri, Texas
2018-08-02
Active, closed
AbbVie
Phase 2
156
Colorado, Florida, Georgia, Illinois, Massachusetts, New Jersey, New York, North Carolina
2018-04-02
Active, closed
BioLineRx, Ltd.
Phase 3
180
California, Florida, Illinois, Maryland, Minnesota, Missouri, Ohio, Texas
2018-03-23
Active, closed
PRospective Multiple Myeloma Impact Study
NCT02911571Multiple Myeloma
SkylineDx
Not applicable
250
District of Columbia, Georgia, New Jersey, New York, North Carolina, Wisconsin
2018-02-27
Active, closed
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
NCT02952508Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugCLR 131
Cellectar Biosciences, Inc.
Phase 2
120
California, District of Columbia, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2017-07-26
Recruiting
Oncotherapeutics
Phase 1
134
California, Florida, Maryland, Washington
2017-02-01
Active, closed
AbbVie
Phase 2
120
Alabama, Arkansas, Florida, Georgia, Illinois, Indiana, Kentucky, Maine
2017-01-19
Active, closed
Celgene
Phase 1/2
466
Arizona, Arkansas, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2016-10-14
Active, closed
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
NCT02477878Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma
DrugRimiducid
Bellicum Pharmaceuticals
Phase 1
10
Georgia, Kansas, New York, Oregon, Texas
2016-07
Recruiting
Karyopharm Therapeutics Inc
Phase 1/2
300
Arizona, California, Colorado, Massachusetts, Nebraska, New Jersey, New York, North Carolina
2015-10
Active, closed
Bristol-Myers Squibb
Observational
2,555
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Iowa
2012-06-13
Rows per page Showing 1–110 of 110
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/multiple-myeloma

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 10 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 110 of those studies listing the condition Multiple Myeloma.

How many Multiple Myeloma trials are recruiting in the US?

50 of the 110 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 58 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Multiple Myeloma), 110 studies
PhaseStudiesRecruitingShare
Phase 327924.5%
Phase 1261123.6%
Phase 1/2261523.6%
Phase 217615.5%
Observational635.5%
Not applicable423.6%
Phase 4221.8%
Early Phase 1110.9%
Phase 2/3110.9%

Most active sponsors

Lead sponsors with the most studies (Multiple Myeloma)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC238
AbbVie136
GlaxoSmithKline123
Pfizer84
Celgene51
Bristol-Myers Squibb42
Regeneron Pharmaceuticals33
All4Cure21
AstraZeneca22
C4 Therapeutics, Inc.21

Top states

Top states (Multiple Myeloma), by number of studies with a site there
StateStudies
California63
Georgia57
Florida56
Colorado41
Arizona38
New York37
Massachusetts32
Illinois31
Michigan29
North Carolina26
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.